53 related articles for article (PubMed ID: 15313888)
1. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome.
Chamuleau ME; Souwer Y; Van Ham SM; Zevenbergen A; Westers TM; Berkhof J; Meijer CJ; van de Loosdrecht AA; Ossenkoppele GJ
Cancer Res; 2004 Aug; 64(16):5546-50. PubMed ID: 15313888
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens.
Li L; Reinhardt P; Schmitt A; Barth TF; Greiner J; Ringhoffer M; Döhner H; Wiesneth M; Schmitt M
Cancer Immunol Immunother; 2005 Jul; 54(7):685-93. PubMed ID: 15627212
[TBL] [Abstract][Full Text] [Related]
3. The MHC Class II Antigen-Processing and Presentation Pathway Is Dysregulated in Type 1 Diabetes.
Gilles A; Hu L; Virdis F; Sant'Angelo DB; Dimitrova N; Hedrick JA; Denzin LK
J Immunol; 2023 Dec; 211(11):1630-1642. PubMed ID: 37811896
[TBL] [Abstract][Full Text] [Related]
4. Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation.
Houtenbos I; Westers TM; Stam AG; de Gruijl TD; Scheper RJ; Ossenkoppele GJ; van de Loosdrecht AA
Cancer Immunol Immunother; 2003 Jul; 52(7):455-62. PubMed ID: 12690520
[TBL] [Abstract][Full Text] [Related]
5. D-2-hydroxyglutarate supports a tolerogenic phenotype with lowered major histocompatibility class II expression in non-malignant dendritic cells and acute myeloid leukemia cells.
Hammon K; Renner K; Althammer M; Voll F; Babl N; Decking SM; Siska PJ; Matos C; Conejo ZEC; Mendes K; Einwag F; Siegmund H; Iberl S; Berger RS; Dettmer K; Schoenmehl R; Brochhausen C; Herr W; Oefner PJ; Rehli M; Thomas S; Kreutz M
Haematologica; 2024 Jan; ():. PubMed ID: 38235501
[TBL] [Abstract][Full Text] [Related]
6. Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance.
Balasubramanian A; John T; Asselin-Labat ML
Biochem Soc Trans; 2022 Apr; 50(2):825-837. PubMed ID: 35343573
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive assessment of the prognostic role of cell adhesion molecules in acute myeloid leukemia.
Cheng J; Han J; Lin C
Transl Cancer Res; 2020 Dec; 9(12):7605-7618. PubMed ID: 35117360
[TBL] [Abstract][Full Text] [Related]
8. B7-Positive and B7-Negative Acute Myeloid Leukemias Display Distinct T Cell Maturation Profiles, Immune Checkpoint Receptor Expression, and European Leukemia Net Risk Profiles.
Antohe I; Dǎscǎlescu A; Dǎnǎilǎ C; Titieanu A; Zlei M; Ivanov I; Sireteanu A; Pavel M; Cianga P
Front Oncol; 2020; 10():264. PubMed ID: 32231996
[TBL] [Abstract][Full Text] [Related]
9. CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival.
Zeiner PS; Zinke J; Kowalewski DJ; Bernatz S; Tichy J; Ronellenfitsch MW; Thorsen F; Berger A; Forster MT; Muller A; Steinbach JP; Beschorner R; Wischhusen J; Kvasnicka HM; Plate KH; Stefanović S; Weide B; Mittelbronn M; Harter PN
Acta Neuropathol Commun; 2018 Mar; 6(1):18. PubMed ID: 29490700
[TBL] [Abstract][Full Text] [Related]
10. HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.
Seliger B; Kloor M; Ferrone S
Oncoimmunology; 2017; 6(2):e1171447. PubMed ID: 28344859
[TBL] [Abstract][Full Text] [Related]
11. Improving natural killer cell cancer immunotherapy.
Berrien-Elliott MM; Romee R; Fehniger TA
Curr Opin Organ Transplant; 2015 Dec; 20(6):671-80. PubMed ID: 26414502
[TBL] [Abstract][Full Text] [Related]
12. CD44 and CD74: The promising candidates for molecular targeted therapy in oral squamous cell carcinoma.
Shakib PA; Ensani F; Abdirad A; Valizadeh B; Seyedmajidi M; Sum S
Dent Res J (Isfahan); 2015; 12(2):181-6. PubMed ID: 25878685
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell-based immunotherapy for myeloid leukemias.
Schürch CM; Riether C; Ochsenbein AF
Front Immunol; 2013 Dec; 4():496. PubMed ID: 24427158
[TBL] [Abstract][Full Text] [Related]
14. Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.
Thibodeau J; Bourgeois-Daigneault MC; Lapointe R
Oncoimmunology; 2012 Sep; 1(6):908-916. PubMed ID: 23162758
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
Attar EC; Johnson JL; Amrein PC; Lozanski G; Wadleigh M; DeAngelo DJ; Kolitz JE; Powell BL; Voorhees P; Wang ES; Blum W; Stone RM; Marcucci G; Bloomfield CD; Moser B; Larson RA
J Clin Oncol; 2013 Mar; 31(7):923-9. PubMed ID: 23129738
[TBL] [Abstract][Full Text] [Related]
16. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
17. Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation.
van Luijn MM; Chamuleau ME; Ossenkoppele GJ; van de Loosdrecht AA; Marieke van Ham S
Oncoimmunology; 2012 Mar; 1(2):211-213. PubMed ID: 22720245
[TBL] [Abstract][Full Text] [Related]
18. Class II-associated invariant chain peptide expression represents a novel parameter for flow cytometric detection of acute promyelocytic leukemia.
van Luijn MM; Westers TM; Chamuleau ME; van Ham SM; Ossenkoppele GJ; van de Loosdrecht AA
Am J Pathol; 2011 Nov; 179(5):2157-61. PubMed ID: 21907692
[TBL] [Abstract][Full Text] [Related]
19. Enhanced expression of CD74 in gastrointestinal cancers and benign tissues.
Gold DV; Stein R; Burton J; Goldenberg DM
Int J Clin Exp Pathol; 2010 Nov; 4(1):1-12. PubMed ID: 21228923
[TBL] [Abstract][Full Text] [Related]
20. Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation.
van den Ancker W; van Luijn MM; Ruben JM; Westers TM; Bontkes HJ; Ossenkoppele GJ; de Gruijl TD; van de Loosdrecht AA
Cancer Immunol Immunother; 2011 Jan; 60(1):37-47. PubMed ID: 20859626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
